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Summary The role of carcinoembryonic antigen (CEA), gamma glutamyl transpeptidase (yGT),
phosphohexose isomerase (PHI), pseudouridine (i/) and acute phase reactant proteins (C-reactive protein
(CRP) a1-antichymotrypsin (ACT) and a,-acid glycoprotein (AGP)) in assessing the prognosis of gastro-
intestinal neoplasms and the discriminant function in distinguishing benign from malignant diseases of the
GI tract was examined. In stomach cancer pre-operative levels of CRP can help in the identification of the
patients with a resectable tumour; the pre-operative biochemical measurements do not give any further
information on prognosis once stage and site are taken into account.
In colorectal cancer pre-operative ACT levels give additional prognostic information once the clinical
factors, Dukes stage, sex and age have been accounted for; PHI levels are on the border line of significance. A
discriminant function has been devised using sex, CEA, i, yGT, ACT and PHI that can identify 89% of Dukes
"D" patients prior to surgery with a misclassification of 7% of other cases of colorectal cancer.
A discriminant function using all the biochemical variates separated the cancer from non-cancer patients.
The false positive rate for cancer was 16% and a false negative rate of 19%, when the cut-off level was set at
0.7.
There is now a large body of evidence that pre-
operative high blood levels of carcinoembryonic
antigen (CEA) in colorectal cancer and in gastric
cancer will be associated with a decreased survival,
especially of patients with locally advanced or
metastatic tumours (Staab et al., 1981, 1982;
Wanebo et al., 1978). However, the prognostic
significance of slightly raised levels of CEA is still
debatable (Goslin et al., 1980; Blake et al., 1982;
Steel et al., 1982). A combination of CEA and
acute phase reactant proteins (APRPs) have been
used in the pre-operative assessment of stomach
cancer (Rashid et al., 1982) and colorectal cancer
(Ward et al., 1977) and their value assessed by
multivariate analysis. This experience suggests that
the combination of tumour-associated factors, such
as CEA, and various non-specific reactions to the
presence of tumour, constitute a better set of
prognostic indicators than any of these factors
when used alone. Extending this argument, it
seemed important to test whether a combination of
several non-specific changes that can occur in
gastrointestinal cancer, might be used as a basis of
identifying the patients who are more likely to have
malignant disorders of the gastrointestinal tract,
compared to those who are eventually
demonstrated to have benign disorders. In this
paper, we discuss the combination of the pre-
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operative measurement in serum of CEA, acute
APRPs, gamma-glutamyl transpeptidase (y-GT),
phosphohexose isomerase (PHI), and pseudouridine
(0) as the database for a multivariate analysis.
Depending on the disease, an objective statistical
analysis can be employed to select a combination of
these analytes to help to provide the clinician with
information regarding either the prognosis of a
confirmed cancer, or the probability that the
patient has got a neoplasm.
Patients and methods
One hundred patients with biopsy-proven gastric
cancer, 100 patients with colorectal cancer and 73
patients with benign diseases of the gastrointestinal
tract, requiring endoscopy, were investigated. The
study was commenced in 1978, and the last patient
was entered in August 1981. During the follow-up
period, 75% of patients with gastric cancer and
50% of those colorectal cancer have died.
Analytical methods
Blood samples were collected by venipuncture,
allowed to clot at room temperature, then
centrifuged at 3000rpm and serum stored at -25°C
for subsequent analysis.
Carcinoembryonic antigen (CEA) was determined
using Phadebas CEA Prist kits supplied by
Pharmacia Diagnostics AB (Uppsala, Sweden).
(C The Macmillan Press, 1983342 J. DE MELLO et al.
Gamma-glutamyl transpeptidase (yGT) was
measured at 37°C by the method of Haesen (1972),
using a Technicon Autoanalyser II.
Phosphohexose isomerase (PHI) was assayed at
25°C using kits supplied by Behringwerke
(Marburg/Lahn, Germany).
Acute phase reactant proteins-C-reactive protein
(CRP), a,-acid glycoprotein (AGP) and al-
antichymotrypsin (ACT)-were measured by single
radial immunodiffusion using the method of
Mancini et al. (1965) using antisera and standards
obtained from Behringwerke, Marburg/Lahn,
Germany.
Serum pseudouridine (i/) concentration was
measured by high performance liquid
chromatography by the method described by Davis
et al. (1977) and modified by Higley et al. (1982).
Statistical analysis
Discriminant analysis. Logistic discriminant
analysis (Anderson, 1972; and Albert, 1982) has
been employed in this study because of the need for
multivariate tests, which take into account the
inter-relationship between measurements, and also
makes no assumptions about the distributions of
these measurements. The terms are added to the
model sequentially and at each step the statistical
significance for each term, not already in the
model, is calculated and a term will be accepted at
the 5% level (P<0.05). The goodness-of-fit for the
final model can be calculated and a large P-value,
for this indicates that the data are consistent with
the model. Biochemical measurements with skewed
distributions in both groups were given a
logarithmic transformation. The analysis was
performed using the statistical package BMDP-81,
sub-routine PLR on the University of Leeds'
AMDAHL 470 computer.
Survival analysis
A multivariate regression model (Cox 1972) was
used to assess the effect of clinical and biochemical
measurements on prognosis and also the effect of a
measurement, once other terms had been taken into
account. A sequential investigation of the terms
influencing survival has been performed and the
criterion for including the term into the model is
that it contributes additional information to that
already clinically known. Continuous measurements
of the biochemical analytes have been used as it
was felt that information would be lost by using
arbitrary cut-off levels. Survival curves were
obtained using the method of Breslow (1974). The
residual method (Cox & Snell 1968) has been used
to check the validity of the model.
Results
Gastric cancer
Pre-operative assessment. First, we tested whether
it is possible to identify pre-operatively those
patients in whom surgery was of little or no benefit
to the patient (non-resectable, no bypass) or only a
palliative procedure was performed (Group A) and
those in whom a radical resection was justified
(Group B). Logistic discriminant analysis identified
that the pre-operative levels of CEA, yGT, ACT
and CRP were discriminating factors individually,
but once CRP had been taken into account no
other measurement gave additional information.
Figure 1 shows the level of CRP in the two risk
groups and using a cut-off level of 20mgl-1 we
could identify 22/44 (50%) of the group A patients
(16 were non-resectable and 6 had palliative
resection). If we adopted a CRP.20mgl-1 as a
discriminant, 6 patients from the radical resection
group (B) would be included, but only 2 of these 6
survived >6 months.
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Figure 1 Distribution of CRP level in the operable
and inoperable gastric cancer patients.
Second, the contribution of the information listed
in Table I and the pre-operative biochemical
measurements in the assessment of prognosis were
tested. This demonstrated that stage is clearly a
prognostic factor, and that an improvement in the
accuracy of the prediction could be achieved by
adding the anatomical site of the primary tumour
0 - - I'll90orMULTIVARIATE ANALYSIS IN GASTROINTESTINAL CANCER
Table I Description of patients and clinical measurements
Benign gastro-
intestinal
Gastric cancer Colorectal cancer disease
No. ofpatients 100 100 73
Age range (years) 41-91 33-87 31-84
Median age 69 68 62
No. ofmales 69 50 38
Stage of tumour Stage I (6%) Dukes stage A (3%)
(Stomach, UICC, 1978) Stage II (13%) Dukes stage B (45%)
colorectal, Dukes 1938 Stage III (31%) Dukes stage C (34%)
Stage IV (50%) Metastatic (18%)
Histology tumour grade GI (14%) GI (48%)
(UICC 1978) G2 (24%) G2 (39%)
G3 (54%) G3 (12%)
Gx (8%) Gx (1%)
Operative procedure Non-resectable (38%) Non-resectable (14%)
Palliative (12%) Palliative (14%)
Resectable (50%) Resectable (72%)
Primary tumour site Upper third (25%) Colon (56%)
Middle third (28%) Rectal (44%)
Lower third (47%)
(Table II), but once these factors were taken into
account the histology and biochemical variates did
not add further information. Following the report
of (Staab et al., 1982) the assessment of prognosis
was also performed excluding those patients who
died within 4 weeks of their operation; both stage
and site remained the most important prognostic
factors.
Table II Median survival time (weeks) for gastric cancer
patients according to stage and site of tumour
Stage I& II Stage III Stage IV
All sites 63 50 13
Upper third 35 29 3
Middle third 54 35 9
Lower third 79* 64* 20
*Survival time could be longer as based on relatively
few patients.
Colorectal cancer
Prognosis. Assessment of prognosis in colorectal
cancer is a more straightforward analysis as this
form of neoplasm is not associated with a high
post-operative mortality. Three Dukes stage A
patients and 3 patients who died from causes
unrelated to cancer were excluded from the
analysis. In our patients it was demonstrated that
the Dukes stage was the most important factor
determining the prognosis; Dukes B lesions had a
median survival time of 136 weeks, Dukes C lesions
of 72 weeks and Dukes D lesions of 21 weeks.
Sex was also a prognostic factor in this set with
women on average having a longer survival time
than men and once stage is accounted for in the
model then age becomes a prognostic factor.
Nevertheless, it was important to enter the clinical
terms in the model (stage, sex and age) before
examining the contribution of biochemical
measurements. While the biochemical markers
y-GT, PHI, ACT, CRP and AGP individually are
prognostic factors (Table III), once the clinical
terms, sex, age and Dukes stage are included into
the model then the pre-operative levels of y-GT,
Table III Relationship between clinical
measurements/pre-operative biochemical
measurements and survival
Terms in model %2 p
Site of tumour 0.75 NS
Sex 5.14 <0.025
Age 0.26 NS
Differentiation 1.04 NS
CEA 10.48 <0.005
y-GT 10.48 <0.005
PHI 14.75 <0.001
ACT 23.05 <«0.001
Dukes stage 37.30 <<0.001
CRP 14.62 <0.001
AGP 5.18 <0.025
i/i 0.04 NS
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Table IV Relationship between pre-operative biochemical
measurements and survival, once clinical measurements
have been accounted for
Terms in model X P
Sex+Age+Dukes stage
Sex+Age+Dukes+CEA 0.03 NS
Sex+Age+Dukes+y-GT 0.97 NS
Sex+Age+Dukes+PHI 9.06 <0.005
Sex+Age+Dukes+ACT 11.49 <0.001
Sex+Age+Dukes+CRP 7.07 <0.01
Sex+Age+Dukes+AGP 4.38 <0.05
Sex+Age+Dukes+ / 0.08 NS
CEA and AGP no longer provide additional
information (Table IV). However, ACT, PHI, CRP,
and AGP all contained prognostic information not
given by the various clinical terms in the model.
The final prognostic model contains the terms
Dukes stage, sex, age, and ACT. Once ACT had
been included in the model no other biochemical
measurement was statistically significant at the 5%
level (P<0.05) but PHI was only just below this
level (P=0.06) and so in a larger study PHI may
have been included in the model. Figure 2 shows
the way in which the model predicts survival
differences of male patients aged 67 years with
tumours of various stages, and how the survival
probability is worse in patients who have a high
ACT level, compared to those in which these levels
are within normal limits. This analysis clearly
demonstrates the biological advantage to the
patient of having no rise of acute phase proteins
prior to surgery.
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Figure 2 Estimated survival probabilities in colorectal
cancer ofmale patients aged 67 years, and the effect of
a raised ACT (1.1 gI-) compared with a normal ACT
(0.67g -1) in relation to Dukes staging.
Pre-operative: Discrimination of stage. The
colorectal cancer group of patients had a much
smaller percentage of advanced tumours than the
patients presenting with gastric cancer. Dukes stage
D tumours by definition had distant metastases and
so it would be useful to know if these patients
could be identified before laparotomy. Individually
all the biochemical markers gave a significant
difference (P<0.0001) between the Dukes stage D
and Dukes stages A, B, and C. Logistic
discrimination was used to find the best
combination of pre-operative measurements that
divided up the two groups. The discriminant
-function was
y= -19.4+ 1.1 xSex+1.3
x ln(CEA)+0.9ln(yGT)
+ 1.6 xln(PHI+2.1 xACT)
Female= -1, Male= 1,
and Probability (Metastases)=exp(y)/(1 +exp(y)).
Using a cut-off level of 0.24 (Figure 3) the
discriminant function identified 16/18 (89%) of the
Dukes stage D patients but only misclassified 6/82
(7%) of the other patients; all those misclassified
had Dukes stage C tumours. These latter patients
had a shorter survival time than those that were
correctly classified.
Discriminant analysis of malignant and benign
gastrointestinal disease
A multivariate stepwise logistic analysis was run
using 6 of the 7 analytes to test their discriminant
power to separate a population with known gastric
or colorectal cancer from patients known to have
benign disease of the gastrointestinal tract. As PHI
data were not available for all the benign patients,
these were excluded. The model used CEA, y-GT,
ACT, CRP, and age, and sex were not shown to
have discriminating power and AGP was not
included in the model as it is correlated with ACT
(r=0.46) and CRP (r=0.490). The discriminant
function was as follows:
y= 1.17 xln(CEA)+0.78 x ln(-GT)+3.52 x ACT
+0.38 xln(CRP)+0.42 xln(0)-6.86,
and Probability (Cancer) =exp(y)/(l+ exp(y))
and this equation separated the two populations as
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Figure 3 Histogram of predicted probabilities of metastases for Dukes stage D patients and Dukes stages A,
B, and C patients.
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The optimum separation that can be achieved
with this combination of analytes uses a cut-off
level point of 0.7. This position is indicated on
Figure 4 and applying this criterion the false
positive rate for cancer will be 16% and the false
negative rate will be 19%. Patients with benign
disease who were allocated to the cancer group on
the basis of the analysis included a number of
diseases. The small numbers in each disease type
made it impossible to say whether any one disease
contributed a higher percentage of false positive
patients to the cancer group. However, out of those
32 patients with cancer who were assigned to the
non-malignant group, 12 were from the colon and
rectal cancer group and 20 from the gastric cancer
group. Patients with a tumour in the middle third
of the stomach had a higher percentage 9/28 (32%)
assigned to the benign group independent of the
stage, as compared to the tumours in the upper
third 2/25 (8%) and lower third 9/47 (19%).
Interestingly, this discriminant function did allocate
a high proportion of the earlier stage cancers to the
malignant group, 14/19 (74%) stage I and II in
gastric cancer and 40/48 (83%) of Dukes A and B
colorectal cancers.
Discussion
Long term observation has now revealed the extent
to which pre-operative measurements of CEA can
help determine the prognosis of colorectal cancer.
The results of several major series involving many
hundred patients have been published during the
past few years. Some of the investigators are
convinced by the sub-sets that can be created
within the Dukes (1938) or TNM classifications of
colorectal cancer (UICC, 1978) by adding an
arbitrary discriminant level of CEA, for example
>5 ngml -1 carry important prognostic information
(Staab et al., 1981; Wanebo et al., 1978; Szymendra
et al; 1982); for others the prognostic significance
of a low CEA level is dubious. (Goslin et al., 1980;
Blake et al., 1982).
A more critical examination restricted to 563
patients with Dukes stage B or C tumours
undergoing curative resection found that a raised
pre-operative CEA only had a significant effect on
prognosis in Dukes C lesions of the colon but not
of the rectum (Steel et al., 1982). Occult hepatic
metastases are frequently the reason for failure of a
curative resection of a colorectal cancer. Imaging
techniques can demonstrate such lesions in patients
where the pre-operative CEA is normal (Findlay &
McArdle, 1982). However, CT scanning is
impractical in general hospital practice, especially
as the presence of occult metastases will not
influence any decision to resect the primary
tumour.
Ward et al. (1977) suggested that ARPSs could
be used in conjunction with the preoperative CEA
level to separate metastatic from non-metastatic
colorectal cancer. They derived a logistic
discriminant based on CEA, x1-antitrypsin and
haptoglobin levels. Subsequently it has been felt
that these two acute phase proteins have the
disadvantage of showing considerable genetic
variation in their response to the inflammation
produced by a cancer. (Cooper & Stone, 1979.) In
the current study it can be seen that on adding sex,
GT, and PHI levels to the equation a proportion of
the Dukes D and some C cases (most with a short
survival time) could be identified prior to surgery.
The level of APRPs can separate good and poor
prognostic groups within the subsets provided by
the classical staging systems for bladder cancer
(O'Quigley et al., 1981), lung cancer (Bradwell et
al., 1979), and cancer of the cervix (Te Velde et al.,
1979).
In the majority of patients who eventually die of
cancer following resection of a colorectal cancer,
the CRP and ACT levels tend to rise progressively
as the cancer burden increases and the patient
approaches the terminal phase of the illness, so that
they were raised in 49/55 (89%) patients 3 months
prior to death (Cooper & Turner, 1980). A similar
phenomenon is observed in ovarian cancer
(Meerwaldt et al., 1983). Serum CEA concentration
in cancer, reflects the integral of the production of
CEA by normal and malignant cells, the tumour
cell mass and the metabolism of the CEA. By
contrast, elevated serum levels of CRP, ACT or
AGP, in a patient with cancer in the absence of
infection predominantly reflect the effects of
stimulation of the liver to increased APRP synthesis
in response to blood borne chemical signals derived
from tissue destruction in any site (Cooper &
Stone, 1979; Kushner, 1982).
In carcinoma of the stomach it is of interest that
the patients in this study indicated that it is clinical
factors that are predominant in determining the
prognosis once the stage has been assessed at
laparotomy. The pre-operative level of CRP can
draw attention to those patients in whom a
resectable operation is highly unlikely. Perhaps with
a tendency of some surgeons to adopt a more
conservative attitude to the management of
advanced gastric cancer, a stratification of the
patients by a simple procedure such as the
measurement of pre-operative CRP level may be of
help in the decision to offer any form of surgery.
Some patients may be better served by supportive
care alone.
This study has begun to explore the contribution
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cancer. The patients are a typical cross section of
those referred to the Gastroenterology services of a
General hospital. At this time our aim is to test
whether a simple biochemical study is a feasible
way to provide a warning that cancer is highly
likely and to find out which analytes should be
included. This study has not covered all the
analytes that might be used in the studies of
prognosis or discrimination; galactosyl/transferase
isoenzyme II is a good candidate for further study.
(Podolsky et al., 1978, 1981.) This enzyme appears
to be raised in a high proportion of gastrointestinal
cancers, its level reflects stage and can help
discriminate cancer from non-malignant conditions.
The next phase of the study of this type is to
determine whether biochemical tests can be used to
optimize the sequence of radiological and
endoscopic investigations that are. required to
establish a diagnosis. Most of all it is important to
know if a battery of tests can be applied to patients
with minimal symptoms in the hope of detecting
early cancers, and thereby overcome the severe
limitations of using a single analyte such as CEA
which is acknowledged to be generally unhelpful in
the search for an early gastrointestinal cancer.
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